

**Eesti ravimistatistika  
2002-2006**

**Estonian Statistics on Medicines  
2002-2006**



**Ravimiamet**  
**State Agency of Medicines**

**Eesti ravimistatistika**  
**2002-2006**

**Estonian Statistics on Medicines**  
**2002-2006**

Toimetanud/ Edited by: Aivi Themas  
Autoriõigus/ Copyright: Ravimiamet, 2007

Väljaande andmete kasutamisel või tsiteerimisel palume viidata allikale.  
When using or quoting the data included in this issue, please indicate the source.

Kirjastanud/ Published by: Ravimiamet  
State Agency of Medicines  
Nooruse 1, 50411 Tartu  
Telefon 737 4140  
Faks 737 4142  
E-post sam@sam.ee

Trükkinud/ Printed by: AS Triip  
Küljendanud/ Layout by: Imre Heero

ISSN 1406-0957 (Trükis)  
ISSN 1406-0949 (Võrguväljaanne)

## Eessõna

Käesolev raamat on statistiline kokkuvõtte Eesti ravimikasutamise andmetest aastatel 2002-2006. Tulemused põhinevad ravimite hulгимүүjate poolt esitatud aruannetel, mis kajastavad ravimite müüki hulгимүүjatel üld- ja haiglaapteekidele ning teistele asutustele.

Eesti ravimikasutamise andmete võrreldavuse tagamiseks teiste riikidega on tulemused esitatud anatoomilis-terapeutilis-keemilise (ATC) klassifikatsiooni alusel, defineeritud päevadooside arvuna tuhande inimese kohta ööpäevas (DPD/1000/ööpäevas). Defineeritud päevadoos (DPD) on Maailma Terviseorganisatsiooni poolt välja töötatud kokkuleppeline suurus enamiku kasutusel olevate ravimite jaoks. DPD ei tähista ravimi tegelikku või soovitatavat annust, sest ravimil võib olla mitu näidustust ning manustatud annused sellele vastavalt ka erineda. Definitsiooni kohaselt on defineeritud päevadoos (DPD) ravimi tavaline ööpäevane annus täiskasvanul vastavalt peamisele kasutamisenäidustusele. Käesolevas raamatus on kasutusel 2006. aastal jõustunud ATC klassifikatsioon ja defineeritud päevadoosid.

Ravimite kasutamise statistilised andmed esitatakse defineeritud päevadooside arvuna tuhande inimese kohta ööpäevas (DPD/1000/ööpäev), mis näitab ravimi kasutamise intensiivsust populatsioonis – mitu inimest tuhandest võis iga päev kasutada seda ravimit defineeritud annuses.

## Foreword

This book is a statistical summary of the Estonian drug consumption data in 2002-2006. The figures included in the book represent sales from the wholesalers to general and hospital pharmacies and to other institutions.

In order to provide better possibilities for sharing experiences and making comparisons, the Anatomical-Therapeutic-Chemical (ATC) classification of medicines and the Defined Daily Dose (DDD) methodology recommended by the World Health Organization is used. The DDD is the assumed average dose per day for the drug used in its main indication in adults. It is a technical unit of measurement and does not always correspond to the clinical dose actually used. The ATC/DDD version valid from January 2006 is used in the book.

The national consumption statistics are expressed as the number of DDDs per 1000 inhabitants per day (DDD/1000/day). Drug consumption expressed in this way may provide a rough estimate of the proportion of the population within a defined area treated daily with certain drugs.

Näiteks suurus 10 DPD/1000/ööpäevas viitab sellele, et keskmiselt 1% elanikkonnast kasutab antud ravimit igapäevaselt.

Andmete põhjal järelduste tegemisel tuleks kindlasti arvestada sellega, et tegemist on hulгимүүги andmetega ning kõik müüdnud ravimid ei jõudnud tarbijani, ja ka osa apteegist koju viidud ravimiteist võis jääda kasutamata. Samuti on oluline meeles pidada, et mõne ravimi tarvitamine on piiratud vastavate ea- või soogruppidega. Näiteks suukaudsete rasestumisvastaste preparaaside koguarv on jagatud fertiilses eas (15-45 aastat) olevate naiste arvuga. Samas ei ole eagruppe siin raamatus kõikjal kasutatud, näiteks digoksiini kasutavad valdavalt vanemaalised, kuid arvutustes on kasutatud kogu rahvastiku andmeid. Arvutustes on kasutatud Eesti rahvaarvu iga aasta 1. jaanuari seisuga (vt tabel 7).

Lisaks ravimite kasutamise andmetele annab raamat ülevaate ravimituru jaotumisest põhiliste farmakoloogiliste rühmade vahel. Kokkuvõttest on välja jäetud kasvajatevastaste ravimite (v.a. hormoonide antagonistid), üld- ja lokaalanesteetikumide, silmaravimite (v.a. glaukoomi ravimid) ja kõigi dermatoloogiliste ravimite kasutamise andmed, millele on keskmise päevadoosi (DPD) rakendamine ebaotstarbekas. Põhjuseks on ravimite annustamise individuaalsus (dermatoloogilised ravimid), ravimite ühekordne kasutamine (anesteetikumid) või ravimisel väga erinevate manustamisskeemide kasutamine (kasvajatevastased ravimid).

An estimated drug consumption of 10 DDD/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population.

When interpreting the figures provided by the wholesalers it is worth noting that some drugs may still be unused, either in pharmacies or in patient homes. The DDD figure is generally calculated in relation to the total population, although the drug use may be concentrated in certain age groups or particular sex. For example in calculation of the use of oral contraceptives the number of females at the age of 15-45 years is used instead of the total population. On the other hand age groups are not always used in this book. For example, elderly people mainly use digoxine, but instead of the age groups the total population is used. All calculations use the population figure as of the 1st of January for each year (see table 7).

In addition to the drug consumption data the current book provides an overview of the distribution of medicine sales between main ATC groups. For several important drug groups (antineoplastic drugs, anesthetics, dermatological and ophthalmological preparations) the DDD is not applicable, so those drugs lay beyond the scope of this study. The DDD of a drug can be very difficult to establish, as the drug dose depends on indications, individuals and therapeutic practice. The premises on which the data are based should always be considered when interpreting and evaluating the data.

## Ülevaade ravimiturust

## Overview of the medicinal products market

Eesti ravimituru maht 2006. aastal hulгимүүgi hindades oli 2261 miljonit Eesti krooni (144 miljonit EUR vasta-valt), mis on 12,4% suurem võrreldes 2005. aastaga.

In 2006, sales of medicines in Estonia at wholesale prices totalled 2216 million Estonian kroons (144 million EUR accordingly), a 12,4% increase relative to 2005.

**Table 1. Ravimituru maht hulгимүүgi hindades 2002-2006.**

**Table 1. Total sales of medicinal products at wholesale prices 2002-2006.**

	2002	2003	%	2004	%	2005	%	2006	%
Ravimituru maht miljonites Eesti kroonides <i>Medicinal products market in million Estonian kroons</i>	1473	1595		1920		2012		2261	
			8,3		20,4		4,8		12,4
Ravimituru maht miljonites eurodes <i>Medicinal products market in million EUR</i>	94	102		123		128		144	

% kirjeldab muutust võrreldes eelneva aastaga.

% *The difference in percents compared to the previous year.*

2006. aastal oli Eestis tegevusluba omavaid humaanravimite hulгимүү-jaid 45, neist 28 müüsid ravimeid üld- ja haiglaapteekidele ning teistele asutustele.

In 2006, there were 45 wholesalers who held an activity licence to sell human medicines and 28 of them sold medicines to general and hospital pharmacies and other institutions.

**Table 2. Tegevusluba omavate hulгимүүjate arv Eestis 2002-2006.**

**Table 2. Number of wholesalers with activity licence in Estonia 2002-2006.**

	2002	2003	2004	2005	2006
Hulгимүүjad (humaanravimid ja veterinaarravimid*) <i>Wholesalers (human and veterinary medicines*)</i>	35	36	38	46	45
Hulгимүүjad (ainult veterinaarravimid) <i>Wholesalers (veterinary medicines only)</i>	11	9	9	9	8
Hulгимүүjate arv kokku <i>Total number of wholesalers</i>	46	45	47	55	53

\*Veterinaarravimite käitlemisõigus on vastava eritingimuse olemasolul.

\**Special requirements are needed to trade veterinary medicines.*

7 suurima turuosaga hulгимүүajat kata-  
vad enam kui 90% kogu ravimiturust.

7 leading wholesalers cover more than  
90% of the medicinal products market.

**Tabel 3. Enim ravimeid müünud hulгимүүajat ja nende osakaal ravimiturul (%).**

*Table 3. The leading wholesalers in the medicinal products market and their market share (%).*

Ravimite hulгимүүaja <i>Wholesaler</i>	2002	2003	2004	2005	2006
Tamro Eesti OÜ	30,9	30,1	29,9	30,5	30,2
Magnum Medical OÜ	48	47,8	42,4	25,9	26,7
Apteekide Koostöö Hulгимүүaik OÜ			2,5	15	12,9
OÜ Nordic Pharmac	2,5	3,1	4,7	10	11,6
AS Oriola	3,4	4,9	5,8	5,9	6,7
AS TopMed	4,7	4,4	4,6	4,9	4,4
AS Pharmac MS	3,2	3,2	3	1,9	1,9

Andmed on järjestatud 2006. aasta tulemuste alusel kahanevalt.

*The data is sorted by the year 2006, descending.*

**Tabel 4. Ravimite müük ATC rühmade lõikes (%).**

*Table 4. Sales of drugs according to the ATC main groups (%).*


	ATC rühm <i>ATC main group</i>	2002	2003	2004	2005	2006
C	Kardiovaskulaarsüsteem <i>Cardiovascular system</i>	23,7%	21,8%	21,8%	20,1%	18,1%
N	Kesknaervisüsteem <i>Nervous system</i>	12,7%	13,6%	13,1%	13,4%	13,2%
A	Seedetrakt ja ainevahetus <i>Alimentary tract and metabolism</i>	13,6%	13,6%	13,4%	12,9%	12,6%
J	Infektsioonivastased ained <i>Antibiotics for systemic use</i>	9,9%	9,3%	8,9%	9,1%	9,5%
L	Kasvajatevastased ja immuunmoduleerivad ained <i>Antineoplastic and immunomodulating agents</i>	5,0%	5,6%	7,1%	8,1%	8,8%
R	Hingamissüsteem <i>Respiratory system</i>	7,6%	7,9%	7,5%	7,8%	7,9%
M	Skeleti-lihassüsteem <i>Musculo-skeletal system</i>	7,3%	6,7%	6,8%	6,9%	7,0%
G	Urogenitaalsüsteem ja suguhormoonid <i>Genito urinary system and sex hormones</i>	6,4%	6,5%	6,5%	6,8%	6,8%
B	Veri ja vereloomeorganid <i>Blood and blood forming organs</i>	5,0%	5,8%	5,6%	5,2%	5,5%
D	Dermatoloogilised preparaadid <i>Dermatologicals</i>	3,9%	3,8%	3,8%	4,1%	3,9%
S	Meeleelundid <i>Sensory organs</i>	1,9%	2,2%	2,2%	2,4%	2,7%
V	Varia <i>Various</i>	1,5%	1,8%	2,0%	1,6%	1,8%
H	Süsteemsed hormoonpreparaadid, va suguhormoonid ja insuliinid <i>Systemic hormonal preparations, excl sex hormones and insulins</i>	1,0%	1,1%	1,1%	1,1%	1,0%
P	Parasiidivastased ained, insektiitsiidid ja repellendid <i>Antiparasitic products, insecticides and repellents</i>	0,3%	0,4%	0,4%	0,4%	0,4%

Andmed on järjestatud 2006. aasta tulemuste alusel kahanevalt.

*The data is sorted by the year 2006, descending.*



**Ravimituru jaotus üld- ja haiglaapteekide ning teiste asutuste vahel ATC rühmade lõikes, 2006.**  
*The distribution of medicine sales between general and hospital pharmacies and other institutions according to the ATC main groups, 2006.*



**Table 5. 20 enam kasutatud toimeainet aastal 2006.**

*Table 5. 20 leading active substances in 2006.*

Nr	Toimeaine	Active Substance	DPD/1000/ööpäevas DDD/1000/day
1	atsetüülsalitsüülhape+ magneesiumhüdroksiid	Acetylsalicylic acid + magnesium hydroxide	43,46
2	enalapriil	Enalapril	41,83
3	ramipriil	Ramipril	41,82
4	askorbiinhape	Ascorbic acid	29,69
5	amlodipiin	Amlodipine	28,76
6	enalapriil+hüdroklorotiasiid	Enalapril+hydrochlorothiazide	26,21
7	ibuprofeen	Ibuprofen	21,58
8	metoprolool	Metoprolol	18,56
9	ksülometasoliin	Xylometazoline	17,75
10	diklofenak	Diclofenac	15,39
11	fosinopriil	Fosinopril	15,11
12	isosorbiitmononitraat	Isosorbide mononitrate	14,22
13	digoksiin	Digoxin	12,87
14	atsetüülsalitsüülhape	Acetylsalicylic acid	11,52
15	multivitaamiinid+mineraalained	Multivitamins + minerals	11,02
16	felodipiin	Felodipin	8,72
17	hüdroklorotiasiid	Hydrochlorothiazide	8,44
18	zopikloon	Zopiclone	8,12
19	omeprasool	Omeprazol	7,62
20	ranitidiin	Ranitidine	7,60

**Tabel 6. 20 enam müüdüd preparaati (2006, käive Eesti kroonides).**

**Table 6. 20 leading preparations (2006, turnover in Estonian kroons).**

Nr	Ravimpreparaat <i>Preparation</i>	Müügiloa hoidja <i>Marketing Authorisations Holder</i>	Käive <i>Turnover</i>	ATC kood <i>ATC code</i>
1	BETALOC ZOK	AstraZeneca AB	49 598 138	C07AB02
2	CARDACE	Sanofi-Aventis Deutschland GmbH	24 751 115	C09AA05
3	LANTUS	Sanofi-Aventis Deutschland GmbH	20 749 514	A10AE04
4	NORVASC	Pfizer Europe MA EEIG	19 312 079	C08CA01
5	NOVOMIX 30 FLEXPEN	Novo Nordisk A/S	18 304 575	A10AB05
6	NEORECORMON	Roche Registration Limited	17 842 680	B03XA80
7	MONOPRIL	Bristol-Myers Squibb Eesti AS	17 819 919	C09AA09
8	SERETIDE DISKUS	Glaxo Wellcome Operations	16 174 124	R03AK82
9	CO-RENITEC	Merck Sharp & Dohme OÜ	16 092 439	C09BA02
10	NOVORAPID FLEXPEN	Novo Nordisk A/S	15 656 949	A10AB05
11	VISIPAQUE	Amersham Health AS	14 629 924	V08AB09
12	PEGASYS	Roche Registration Limited	14 536 892	L03AB11
13	MABTHERA	Roche Registration Limited	14 203 332	L01XC02
14	IMDUR	AstraZeneca AB	13 990 065	C01DA14
15	ANDROCUR	Schering AG	13 754 521	G03HA01
16	COSOPT	Merck Sharp & Dohme OÜ	13 538 167	S01ED80
17	CIPRALEX	H. Lundbeck A/S	12 835 680	N06AB10
18	IBUMAX	Vitalbans OY	12 760 416	M01AE01
19	IBUMETIN	Nycomed Sefa AS	12 624 583	M01AE01
20	LACIPIL	Glaxo Wellcome Operations	12 488 423	C08CA09

## Ravimite kasutamise andmed

Järgnevatel lehekülgedel on ravimite kasutamise andmed esitatud defineeritud päevadooside arvuna tuhande inimese kohta ööpäevas (DPD/1000/päevas) aastatel 2002-2006.

Arvutused põhinevad hulгимүүjatelt üldapteekidele, haiglaapteekidele ja teistele asutustele müüdnud ravimite kogusel ja ravimi defineeritud päevadoosil.

## Drug Consumption Data

On the following pages drug consumption is expressed as a number of DDDs per 1000 inhabitants per day (DDD/1000/day) for the period 2002 to 2006.

The calculations are based on the volume of sales to general and hospital pharmacies and to other institutions by wholesalers and on the defined daily dose per day for each drug.

**Table 7. Arvutustes kasutatud rahvaarv (www.stat.ee).**

**Table 7. Population figures used in calculations (www.stat.ee).**

Aasta Year	Rahvastik 1. jaanuari seisuga Population of 1 <sup>st</sup> of January	Naiste arv vanuses 15-45 aastat Number of females at age of 15-45 years
2002	1 360 000	300 000
2003	1 360 000	300 000
2004	1 350 000	300 000
2005	1 350 000	300 000
2006	1 340 000	290 000

Naiste arvu on kasutatud DPD/1000/ööpäevas arvutamiseks järgmiste ATC rühmade korral: G02B ja G03A. Teiste rühmade korral on kasutatud kogu rahvastiku andmeid.

The number of females at the age of 15-45 is used to calculate the DDD/1000inh/day for the following ATC groups: G02B and G03A. In other ATC groups the number of total population is used.

Järgnev näide kirjeldab, kuidas on leitud simvastatiini kasutamise andmed.

The following example shows how simvastatin consumption is calculated.

Defineeritud päevadoos simvastatiinile <i>DDD of simvastatin</i>	0,015 g
Müüdnud toimeaine kogus aastas <i>Sold quantity of active substance per year</i>	52 770 g
Rahvastik <i>Population</i>	1 340 000
DPD/1000/ööpäevas <i>DDD/1000 inhabitants/day</i>	$\frac{52770 * 1000}{0,015 * 1340000 * 365} = 7,19$

Saadud tulemus 7,19 DPD/1000/ööpäevas viitab sellele, et 7 inimest tuhandest võis aasta jooksul iga päev kasutada simvastatiini annuses 0,015 g.

The figure of 7,19 DDD/1000/day indicates how many people (in this case 7,19) per 1000 inhabitants may in theory have received the standard dose (0,015 g) of simvastatin.

Lisaks üldistele ravimikasutamise muutustele on aastatel 2002-2006 toimunud mitmeid muutusi ATC-klassifikatsioonis (toimeained on liikunud ühest rühmast teise, lisandunud on uusi toimeaineid) ja ravimite päevadoosides. Ülevaate ATC-klassifikatsioonis aastate jooksul toimunud muutustest leiab WHO kodulehelt <http://www.whocc.no/atcddd>

Osa muutusi on lokaalsed st seotud ravimistatistika koostamise aluseks olevate andmete muutumise ning tarkvara uuendamisega. Ravimite kasutamise statistikast on välja jäetud taimsed droogid ja ravimisarnased preparaadid ning meditsiiniseadmed (sh rasedustestid). Seoses sellega on vähenenud mitme ravimrühma kasutamisanndmed võrreldes eelnevate väljaannetega.

Eelpool kirjeldatud muutustest enam mõjutatud rühmade kasutamise andmetele on lisatud (\*).

Toimeainete ja farmakoloogiliste rühmade nimetused on esitatud ingliskeelsetena, et hõlbustada Eesti andmete võrdlust teiste maadega. Lisaks toimeaine nimetusele on sulgudes esitatud defineeritud päevadoosi väärtus. Kui päevadooside väärtusi ühel toimeainel vastavalt manustamisviisidele oli rohkem kui 3, siis on erinevate väärtuste asemel sulgudes (different DDDs). Kõik päevadoose puudutavad andmed on esitatud WHO kodulehel <http://www.whocc.no/atcddd>

In addition to general changes in drug consumption during the period 2002-2006 there have been many changes related to the updates in ATC-classification and alterations in DDD assignment. The detailed information about the changes in ATC-classification and DDD values are available on the following website <http://www.whocc.no/atcddd>

Some changes are related to the data the statistics are based on and to computer software updates. The herbal substances (that are not classified as herbal medicines), semi-medicinal products and medical devices (including pregnancy test) are excluded from the drug consumption data. Accordingly the drug consumption data in many ATC groups have decreased compared with previous editions.

The drug consumption data strongly influenced by the above mentioned changes are marked with (\*).

The English version of ATC classification is used in order to facilitate comparisons with other countries. The values of the Defined Daily Doses are represented in the parenthesis. If there were more than 3 different DDD-s, instead of the real values the “different DDDs” is written. Detailed information about the assigned DDD-s are available on the following website <http://www.whocc.no/atcddd>

Kui mõne toimeaine kasutamine oli väiksem kui 0,01 DPD/1000/ööpäevas siis on see tabelis märgitud <0,01. Kui toimeainet pole mingil aastal Eestis kasutatud on vastav lahter tühi.

When the DDD/1000 inhabitants/day value was less than 0,01, it is stated as <0,01. When certain substances are not consumed in Estonia during a year the cell is empty.


**Tabel 8. Ühikute ja manustamisviiside esitamisel kasutatud lühendid.**  
*Table 8. Abbreviations used in representing units and route of administration.*

Ühikud <i>Units</i>	Manustamisviis <i>Route of administration</i>
g – gramm; <i>gram</i>	Inhal – inhalatsioon; <i>inhalation</i>
mg – milligramm; <i>milligram</i>	N – nasaalne; <i>nasal</i>
mcg – mikrogramm; <i>microgram</i>	O – suukaudne; <i>oral</i>
ml – milliliiter; <i>milliliter</i>	P – parenteraalne; <i>parenteral</i>
U – ühik; <i>unit</i>	R – rektaalne; <i>rectal</i>
TU – tuhat ühikut; <i>thousand units</i>	SL – keelealune; <i>sublingual</i>
MU – miljon ühikut; <i>million units</i>	TD – transdermaalne; <i>transdermal</i>
	V – vaginaalne; <i>vaginal</i>

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>A</b>	<b>ALIMENTARY TRACT AND METABOLISM</b>					
<b>A01</b>	<b>STOMATOLOGICAL PREPARATIONS</b>	<b>0,18</b>	<b>0,15</b>	<b>0,22</b>	<b>0,48</b>	<b>1,76</b>
<b>A02</b>	<b>DRUGS FOR ACID RELATED DISORDERS</b>	<b>13,10</b>	<b>13,83</b>	<b>15,29</b>	<b>16,97</b>	<b>18,82</b>
<b>A02A</b>	<b>ANTACIDS</b>	<b>0,96</b>	<b>0,97</b>	<b>0,92</b>	<b>0,97</b>	<b>1,16</b>
A02AC	Calcium compounds	0,46	0,50	0,54	0,57	0,66
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	0,39	0,36	0,28	0,27	0,35
A02AX	Antacids, other combinations	0,10	0,10	0,10	0,12	0,14
<b>A02B</b>	<b>DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)</b>	<b>11,58</b>	<b>12,17</b>	<b>13,49</b>	<b>15,03</b>	<b>17,14</b>
A02BA	H2-receptor antagonists	9,83	8,88	8,80	8,98	8,41
	Cimetidine (DDD 0,8 g)	2,52	1,71	1,39	0,47	0,34
	Ranitidine (DDD 0,3 g)	6,40	6,43	6,74	7,97	7,60
A02BC	Proton pump inhibitors	1,71	3,24	4,66	6,01	8,71
	Omeprazole (DDD 20 mg)	1,47	2,53	3,93	5,29	7,62
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	0,04	0,04	0,04	0,03	0,01
<b>A02D</b>	<b>ANTIFLATULENTS</b>	<b>0,55</b>	<b>0,69</b>	<b>0,88</b>	<b>0,97</b>	<b>0,52</b>

#### Haavandtõve ravimite kasutamise (A02B) 2002-2006.

*Consumption of drugs for peptic ulcer and GORD (A02B) 2002-2006.*



DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>A03</b>	<b>DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</b>	<b>5,61</b>	<b>4,92</b>	<b>4,96</b>	<b>4,82</b>	<b>5,07</b>
<b>A03A</b>	<b>DRUGS FOR FUNCTIONAL BOWEL DISORDERS</b>	<b>4,26</b>	<b>3,80</b>	<b>3,86</b>	<b>3,75</b>	<b>3,99</b>
A03AD	Papaverine and derivatives	4,25	3,80	3,86	3,75	3,90
	Papaverine (incl. combinations) (DDD 0,1 g)	0,03	0,01	<0,01	<0,01	<0,01
	Drotaverine (incl. combinations) (DDD 0,1 g)	4,22	3,78	3,85	3,75	3,90
<b>A03B</b>	<b>BELLADONNA AND DERIVATIVES, PLAIN</b>	<b>0,13</b>	<b>0,13</b>	<b>0,12</b>	<b>0,12</b>	<b>0,09</b>
A03BA	Belladonna alkaloids, tertiary amines	0,09	0,10	0,09	0,10	0,09
	Atropine (DDD 1,5 mg)	0,09	0,10	0,09	0,10	0,09
A03BB	Belladonna alkaloids, semisynthetic, quaternary ammonium compounds	0,04	0,03	0,03	0,03	<0,01
<b>A03F</b>	<b>PROPULSIVES</b>	<b>1,20</b>	<b>0,98</b>	<b>0,98</b>	<b>0,95</b>	<b>0,98</b>
A03FA	Propulsives	1,20	0,98	0,98	0,95	0,98
	Metoclopramide (DDD 30 mg)	1,13	0,92	0,94	0,92	0,94
<b>A04</b>	<b>ANTIEMETICS AND ANTINAUSEANTS</b>	<b>0,02</b>	<b>0,03</b>	<b>0,06</b>	<b>0,05</b>	<b>0,07</b>
<b>A04A</b>	<b>ANTIEMETICS AND ANTINAUSEANTS</b>	<b>0,02</b>	<b>0,03</b>	<b>0,07</b>	<b>0,05</b>	<b>0,07</b>
A04AA	Serotonin (5HT3) antagonists	0,02	0,03	0,06	0,05	0,07
<b>A05</b>	<b>BILE AND LIVER THERAPY</b>	<b>2,27</b>	<b>2,37</b>	<b>3,00</b>	<b>3,13</b>	<b>3,09</b>
<b>A05A</b>	<b>BILE THERAPY</b>	<b>0,74</b>	<b>0,49</b>	<b>0,60</b>	<b>0,48</b>	<b>0,22</b>
A05AA	Bile acid preparations	0,48	0,43	0,55	0,44	0,22
A05AX	Other drugs for bile therapy	0,26	0,06	0,05	0,03	*
<b>A05B</b>	<b>LIVER THERAPY, LIPOTROPICS</b>	<b>1,53</b>	<b>1,88</b>	<b>2,40</b>	<b>2,65</b>	<b>2,86</b>
A05BA	Liver therapy	1,53	1,88	2,40	2,65	2,86
<b>A06</b>	<b>LAXATIVES</b>	<b>7,61</b>	<b>7,93</b>	<b>8,87</b>	<b>9,31</b>	<b>10,96</b>
A06AA	Softeners, emollients	0,03	0,03	0,03	0,03	0,03
	Liquid paraffin (DDD 15 g)	0,03	0,03	0,03	0,03	0,03
A06AB	Contact laxatives	6,90	6,91	7,25	6,28	6,15
	Bisacodyl (DDD 10 mg)	3,27	2,75	2,57	3,69	3,89
	Castor oil (DDD 20 g)	0,05	0,05	0,04	0,05	0,05
	Sodium picosulfate (DDD 5 mg)	1,47	1,58	1,68	1,82	2,01
A06AD	Osmotically acting laxatives	0,50	0,80	1,38	2,76	4,53
	Lactulose (DDD 6,7 g)	0,39	0,71	1,33	2,70	4,46
	Macrogol (DDD 10 g)	0,11	0,06	0,05	0,06	0,07

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>A07</b>	<b>ANTIDIARRHEALS, INTESTINAL ANTI-INFLAMMATORY / ANTIINFECTIVE AGENTS</b>	<b>4,10</b>	<b>3,20</b>	<b>2,83</b>	<b>3,24</b>	<b>3,37</b>
<b>A07B</b>	<b>INTESTINAL ADSORBENTS</b>	<b>0,60</b>	<b>0,35</b>	<b>0,12</b>	<b>0,12</b>	<b>*</b>
A07BA	Charcoal preparations	0,60	0,35	0,12	0,12	*
<b>A07D</b>	<b>ANTIPROPULSIVES</b>	<b>0,44</b>	<b>0,49</b>	<b>0,60</b>	<b>0,69</b>	<b>0,69</b>
A07DA	Antipropulsives	0,44	0,49	0,60	0,69	0,69
	Loperamide (DDD 10 mg)	0,44	0,49	0,60	0,69	0,69
<b>A07E</b>	<b>INTESTINAL ANTIINFLAMMATORY AGENTS</b>	<b>0,87</b>	<b>0,96</b>	<b>1,14</b>	<b>1,16</b>	<b>1,23</b>
A07EC	Aminosalicylic acid and similar agents	0,87	0,96	1,14	1,16	1,23
	Sulfasalazine (DDD 2 g)	0,67	0,72	0,88	0,87	0,89
	Mesalazine (DDD 1,5 g)	0,20	0,24	0,26	0,28	0,34
<b>A07F</b>	<b>ANTIDIARRHEAL MICROORGANISMS</b>	<b>1,12</b>	<b>0,61</b>	<b>0,10</b>	<b>0,17</b>	<b>0,23</b>
<b>A07X</b>	<b>OTHER ANTIDIARRHEALS</b>	<b>1,07</b>	<b>0,79</b>	<b>0,87</b>	<b>1,09</b>	<b>1,22</b>
<b>A08</b>	<b>ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS</b>	<b>0,11</b>	<b>0,11</b>	<b>0,19</b>	<b>0,28</b>	<b>0,50</b>
<b>A08A</b>	<b>ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS</b>	<b>0,11</b>	<b>0,11</b>	<b>0,19</b>	<b>0,28</b>	<b>0,50</b>
A08AA	Centrally acting antiobesity products	<0,01	0,01	0,07	0,19	0,41
A08AB	Peripherally acting antiobesity products	0,11	0,10	0,11	0,09	0,09
<b>A09</b>	<b>DIGESTIVES, INCL. ENZYMES</b>	<b>1,32</b>	<b>1,04</b>	<b>1,64</b>	<b>1,53</b>	<b>1,66</b>
<b>A09A</b>	<b>DIGESTIVES, INCL. ENZYMES</b>	<b>1,32</b>	<b>1,04</b>	<b>1,64</b>	<b>1,53</b>	<b>1,66</b>
A09AA	Enzyme preparations	1,31	1,04	1,64	1,53	1,65
<b>A10</b>	<b>DRUGS USED IN DIABETES</b>	<b>18,77</b>	<b>19,20</b>	<b>22,49</b>	<b>21,08</b>	<b>24,92</b>
<b>A10A</b>	<b>INSULINS AND ANALOGUES</b>	<b>6,22</b>	<b>6,85</b>	<b>8,73</b>	<b>8,03</b>	<b>10,03</b>
A10AB	Insulins and analogues for injection, fast-acting	1,88	2,58	3,70	3,86	5,10
A10AC	Insulins and analogues for injection, intermediate-acting	2,35	2,41	2,63	1,94	1,97
A10AD	Insulins and analogues for injection, intermediate-acting combined with fast-acting	1,88	1,67	1,70	1,16	1,19
A10AE	Insulins and analogues for injection, long-acting	0,11	0,18	0,70	1,07	1,77



DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>A10B</b>	<b>ORAL BLOOD GLUCOSE LOWERING DRUGS</b>	<b>12,55</b>	<b>12,35</b>	<b>13,76</b>	<b>12,99</b>	<b>14,89</b>
A10BA	Biguanides	1,90	2,65	3,66	4,66	6,57
	Metformin (DDD 2 g)	1,90	2,65	3,66	4,66	6,57
A10BB	Sulfonamides, urea derivatives	10,64	9,68	10,07	8,30	8,28
	Glibenclamide (DDD 10 mg)	7,00	5,87	5,46	3,98	3,21
	Glipizide (DDD 10 mg)	0,74	0,96	1,36	1,28	1,31
	Gliclazide (DDD 160 mg)	2,53	2,52	2,92	2,75	2,99
	Glimepiride (DDD 2 mg)	0,36	0,32	0,33	0,29	0,77
<b>A11</b>	<b>VITAMINS</b>	<b>73,85</b>	<b>67,18</b>	<b>73,09</b>	<b>66,31</b>	<b>54,82</b>
<b>A11A</b>	<b>MULTIVITAMINS, COMBINATIONS</b>	<b>25,70</b>	<b>18,97</b>	<b>19,13</b>	<b>16,07</b>	<b>11,29*</b>
<b>A11C</b>	<b>VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO</b>	<b>5,72</b>	<b>5,96</b>	<b>6,22</b>	<b>5,32</b>	<b>1,60*</b>
A11CA	Vitamin A, plain (DDD 50 000 U)	0,04	0,03	<0,01	<0,01	*
A11CB	Vitamin A and D in combination	5,51	5,73	5,81	4,56	<0,01*
A11CC	Vitamin D and analogues	0,17	0,20	0,16	0,11	0,91
<b>A11D</b>	<b>VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12</b>	<b>0,30</b>	<b>0,28</b>	<b>0,17</b>	<b>0,10</b>	<b>0,59</b>
A11DA	Vitamin B1, plain	0,30	0,28	0,17	0,10	0,59
	Thiamine (vit B1) (DDD 50 mg)	0,30	0,28	0,17	0,10	0,15
<b>A11E</b>	<b>VITAMIN B-COMPLEX, INCL. COMBINATIONS</b>	<b>12,87</b>	<b>12,57</b>	<b>13,07</b>	<b>11,71</b>	<b>9,17</b>
<b>A11G</b>	<b>ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS</b>	<b>27,56</b>	<b>27,69</b>	<b>32,63</b>	<b>31,23</b>	<b>29,69</b>
A11GA	Ascorbic acid (vit C), plain (DDD 0,2 g)	27,26	27,44	32,18	31,09	29,69
<b>A11H</b>	<b>OTHER PLAIN VITAMIN PREPARATIONS</b>	<b>1,34</b>	<b>1,23</b>	<b>1,31</b>	<b>1,11</b>	<b>1,10</b>
A11HA	Other plain vitamin preparations	1,34	1,23	1,31	1,11	1,10
	Pyridoxine (vit B6) (DDD 0,16 g)	0,17	0,11	0,12	0,05	0,04
	Tocopherol (vit E) (DDD 0,2 g)	1,17	1,12	1,19	1,06	1,06
<b>A11J</b>	<b>OTHER VITAMIN PRODUCTS, COMBINATIONS</b>	<b>0,25</b>	<b>0,40</b>	<b>0,50</b>	<b>0,68</b>	<b>1,30</b>
<b>A12</b>	<b>MINERAL SUPPLEMENTS</b>	<b>4,19</b>	<b>4,10</b>	<b>4,22</b>	<b>4,32</b>	<b>4,96</b>
<b>A12A</b>	<b>CALCIUM</b>	<b>0,46</b>	<b>0,42</b>	<b>0,47</b>	<b>0,44</b>	<b>0,52</b>
	Calcium gluconate (DDD 3 g)	0,15	0,09	0,06	0,01	<0,01
	Calcium carbonate (DDD 3 g)	0,25	0,27	0,32	0,39	0,49
	Calcium acetate anhydrous (DDD 2 g)	0,06	0,06	0,09	0,04	0,01

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>A12B</b>	<b>POTASSIUM</b>	<b>0,07</b>	<b>0,08</b>	<b>0,09</b>	<b>0,07</b>	<b>0,08</b>
	Potassium chloride (DDD 3 g)	0,07	0,08	0,09	0,07	0,08
<b>A12C</b>	<b>OTHER MINERAL SUPPLEMENTS</b>	<b>3,66</b>	<b>3,60</b>	<b>3,66</b>	<b>3,80</b>	<b>4,36</b>
A12CC	Magnesium	0,09	0,11	0,11	0,32	0,21
	Magnesium citrate (DDD 2 g)	0,09	0,11	0,11	0,32	0,21
A12CX	Other mineral products	3,57	3,49	3,55	3,49	4,14
<i>A14</i>	<i>ANABOLIC AGENTS FOR SYSTEMIC USE</i>	<i>0,15</i>	<i>0,13</i>	<i>0,11</i>	<i>0,06</i>	0,08
<b>A14A</b>	<b>ANABOLIC STEROIDS</b>	<b>0,08</b>	<b>0,08</b>	<b>0,09</b>	<b>0,06</b>	<b>0,07</b>
A14AB	Estren derivatives	0,08	0,08	0,09	0,06	0,07
	Nandrolone (DDD 2 mg)	0,08	0,08	0,09	0,06	0,07
<b>A14B</b>	<b>OTHER ANABOLIC AGENTS</b>	<b>0,07</b>	<b>0,05</b>	<b>0,02</b>	<b>&lt;0,01</b>	<b>&lt;0,01</b>


DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>B</b>	<b>BLOOD AND BLOOD FORMING ORGANS</b>					
<b>B01</b>	<b>ANTITHROMBOTIC AGENTS</b>	<b>35,70</b>	<b>37,65</b>	<b>46,58</b>	<b>48,83</b>	<b>57,42</b>
B01AA	Vitamin K antagonists	1,90	2,21	2,74	2,92	3,19
	Warfarin (DDD 7,5 mg)	1,90	2,20	2,74	2,92	3,19
B01AB	Heparin group	0,58	0,68	0,81	0,90	0,98
	Heparin (DDD 10 000 U)	0,16	0,15	0,14	0,14	0,12
	Dalteparin (DDD 2500 U)	0,21	0,22	0,23	0,07	0,04
	Enoxaparin (DDD 2000 U)	0,10	0,19	0,27	0,54	0,47
	Nadroparin (DDD 2850 U)	0,05	0,08	0,13	0,14	0,34
B01AC	Platelet aggregation inhibitors excl. heparin	33,22	34,76	43,30	45,01	53,24
	Acetylsalicylic acid (DDD 1 tablet)	33,15	34,66	42,84	44,73	43,46
<b>B02</b>	<b>ANTIHEMORRHAGICS</b>	<b>0,43</b>	<b>0,42</b>	<b>0,40</b>	<b>0,28</b>	<b>0,23</b>
<b>B02A</b>	<b>ANTIFIBRINOLYTICS</b>	<b>0,03</b>	<b>0,03</b>	<b>0,03</b>	<b>0,03</b>	<b>0,05</b>
B02AA	Amino acids	0,02	0,02	0,02	0,03	0,04
<b>B02B</b>	<b>VITAMIN K AND OTHER HEMOSTATICS</b>	<b>0,40</b>	<b>0,39</b>	<b>0,37</b>	<b>0,25</b>	<b>0,18</b>
B02BA	Vitamin K	0,28	0,28	0,26	0,15	0,09
	Menadione (DDD 10 mg/O; 2 mg/P)	0,27	0,27	0,26	0,15	0,09
B02BX	Other systemic hemostatics	0,13	0,11	0,10	0,09	0,08
<b>B03</b>	<b>ANTI-ANEMIC PREPARATIONS</b>	<b>12,40</b>	<b>13,50</b>	<b>16,89</b>	<b>11,33</b>	<b>7,37</b>
<b>B03A</b>	<b>IRON PREPARATIONS</b>	<b>7,05</b>	<b>7,57</b>	<b>7,36</b>	<b>5,57</b>	<b>3,75</b>
B03AA	Iron bivalent, oral preparations	3,04	3,26	3,38	2,94	2,84
	Ferrous sulfate (DDD 0,2 g)	0,70	0,84	0,90	0,85	1,00
	Ferrous aspartate (DDD 0,2 g)	2,34	2,42	2,48	2,09	1,84
B03AE	Iron in other combinations	4,01	4,30	3,90	1,94	2,24
<b>B03B</b>	<b>VITAMIN B12 AND FOLIC ACID</b>	<b>5,24</b>	<b>5,76</b>	<b>9,33</b>	<b>5,53</b>	<b>3,57</b>
B03BA	Vitamin B12 (cyanocobalamin and analogues)	5,15	5,64	9,23	5,43	3,49
	Cyanocobalamin (DDD 1 mg/O; 20 mcg/P)	5,15	5,64	9,23	5,43	3,49
B03BB	Folic acid and derivatives	0,09	0,11	0,09	0,10	0,07
	Folic acid (DDD 0,4 mg/O; 10 mg/P)	0,09	0,11	0,09	0,10	0,07
<b>B03X</b>	<b>OTHER ANTI-ANEMIC PREPARATIONS</b>	<b>0,11</b>	<b>0,17</b>	<b>0,20</b>	<b>0,23</b>	<b>0,05</b>
B03XA	Other antianemic preparations	0,11	0,17	0,20	0,23	0,05
	Erythropoetin (DDD 1000 U)	0,11	0,17	0,20	0,23	0,05

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>C</b>	<b>CARDIOVASCULAR SYSTEM</b>					
<b>C01</b>	<b>CARDIAC THERAPY</b>	<b>37,50</b>	<b>36,59</b>	<b>37,60</b>	<b>33,96</b>	<b>38,56</b>
<b>C01A</b>	<b>CARDIAC GLYCOSIDES</b>	<b>14,14</b>	<b>12,62</b>	<b>12,44</b>	<b>10,91</b>	<b>12,91</b>
C01AA	Digitalis glycosides	14,13	12,60	12,42	10,90	12,88
	Digoxin (DDD 0,25 mg)	14,12	12,59	12,42	10,89	12,87
C01AC	Strophantus glycosides	0,01	0,02	0,02	0,02	0,03
	G-strophanthin (DDD 0,25 mg)	0,01	0,02	0,02	0,02	0,03
<b>C01B</b>	<b>ANTIARRHYTHMICS, CLASS I AND III</b>	<b>2,36</b>	<b>2,70</b>	<b>3,41</b>	<b>3,85</b>	<b>3,68</b>
C01BA	Antiarrhythmics, class IA	0,01	0,01	<0,01	<0,01	<0,01
C01BB	Antiarrhythmics, class IB	0,38	0,28	0,31	0,33	0,33
C01BC	Antiarrhythmics, class IC	0,29	0,38	0,55	0,65	0,85
C01BD	Antiarrhythmics, class III	1,68	2,03	2,54	2,87	2,49
	Amiodarone (DDD 0,2 g)	1,68	2,03	2,54	2,87	2,49
<b>C01C</b>	<b>CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES</b>	<b>0,69</b>	<b>0,92</b>	<b>1,15</b>	<b>0,84</b>	<b>0,97</b>
C01CA	Adrenergic and dopaminergic agents	0,68	0,92	1,15	0,84	0,97
	Norepinephrine (DDD 6 mg)	0,10	0,29	0,18	0,29	0,04
	Phenylephrine (DDD 4 mg)	0,15	0,16	0,18	0,15	0,16
	Epinephrine (DDD 0,5 mg)	0,40	0,44	0,75	0,37	0,74
<b>C01D</b>	<b>VASODILATORS USED IN CARDIAC DISEASES</b>	<b>19,66</b>	<b>19,24</b>	<b>20,22</b>	<b>17,41</b>	<b>16,65</b>
C01DA	Organic nitrates	19,50	19,20	20,19	17,39	16,63
	Glyceryl trinitrate (DDD 5 mg/O;2,5 mg/SL)	1,66	1,47	1,15	0,78	1,02
	Isosorbide dinitrate (DDD 60 mg/O;20 mg/SL)	2,93	2,47	2,16	1,69	1,38
	Isosorbide mononitrate (DDD 40 mg)	14,90	15,26	16,76	14,79	14,22
C01DX	Other vasodilators used in cardiac diseases	0,16	0,03	0,02	0,02	0,02
<b>C01E</b>	<b>OTHER CARDIAC PREPARATIONS</b>	<b>0,66</b>	<b>1,11</b>	<b>0,38</b>	<b>0,94</b>	<b>4,35*</b>
C01EB	Other cardiac preparations	0,66	1,11	0,38	0,94	4,35*
<b>C02</b>	<b>ANTIHYPERTENSIVES</b>	<b>0,98</b>	<b>0,91</b>	<b>1,42</b>	<b>1,86</b>	<b>2,21</b>
<b>C02A</b>	<b>ANTIADRENERGIC AGENTS, CENTRALLY ACTING</b>	<b>0,26</b>	<b>0,29</b>	<b>0,57</b>	<b>0,75</b>	<b>0,94</b>
C02AC	Imidazoline receptor agonists	0,26	0,29	0,57	0,75	0,94
	Clonidine (DDD 0,45 mg)	0,25	0,17	0,19	0,17	0,15
	Moxonidine (DDD 0,3 mg)	0,01	0,12	0,38	0,58	0,79

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>C02C</b>	<b>ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING</b>	<b>0,53</b>	<b>0,59</b>	<b>0,83</b>	<b>1,09</b>	<b>1,25</b>
<b>C02L</b>	<b>ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION</b>	<b>0,19</b>	<b>0,03</b>	<b>0,02</b>	<b>0,01</b>	<b>0,01</b>
C02LA	Rauwolfia alkaloids and diuretics in combination	0,19	0,03	0,02	0,01	0,01
<b>C03</b>	<b>DIURETICS</b>	<b>17,48</b>	<b>18,22</b>	<b>20,74</b>	<b>20,93</b>	<b>21,65</b>
<b>C03A</b>	<b>LOW-CEILING DIURETICS, THIAZIDES</b>	<b>7,85</b>	<b>8,31</b>	<b>9,21</b>	<b>8,85</b>	<b>8,44</b>
C03AA	Thiazides, plain	7,85	8,31	9,21	8,85	8,44
	Hydrochlorothiazide (DDD 25 mg)	7,85	8,31	9,21	8,85	8,44
<b>C03B</b>	<b>LOW-CEILING DIURETICS, EXCL. THIAZIDES</b>	<b>0,48</b>	<b>0,76</b>	<b>1,08</b>	<b>1,13</b>	<b>1,19</b>
<b>C03C</b>	<b>HIGH-CEILING DIURETICS</b>	<b>6,36</b>	<b>6,33</b>	<b>7,20</b>	<b>7,67</b>	<b>8,75</b>
C03CA	Sulfonamides, plain	6,36	6,33	7,20	7,67	8,75
	Furosemide (DDD 40 mg)	5,57	5,49	6,07	6,20	6,34
	Torsemide (DDD 15 mg)	0,79	0,84	1,13	1,47	2,41
<b>C03D</b>	<b>POTASSIUM-SPARING AGENTS</b>	<b>2,42</b>	<b>2,55</b>	<b>3,01</b>	<b>3,08</b>	<b>3,11</b>
C03DA	Aldosterone antagonists	2,42	2,55	3,01	3,08	3,11
	Spironolactone (DDD 75 mg)	2,42	2,55	3,01	3,08	3,11
<b>C03E</b>	<b>DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION</b>	<b>0,36</b>	<b>0,27</b>	<b>0,24</b>	<b>0,20</b>	<b>0,16</b>
C03EA	Low-ceiling diuretics and potassium-sparing agents	0,30	0,24	0,24	0,20	0,16
C03EB	High-ceiling diuretics and potassium-sparing agents	0,07	0,03	<0,01	<0,01	*
<b>C04</b>	<b>PERIPHERAL VASODILATORS</b>	<b>2,15</b>	<b>1,99</b>	<b>2,14</b>	<b>2,08</b>	<b>2,14</b>
<b>C04A</b>	<b>PERIPHERAL VASODILATORS</b>	<b>2,15</b>	<b>1,99</b>	<b>2,14</b>	<b>2,08</b>	<b>2,14</b>
C04AB	Imidazoline derivatives	0,18	0,09	<0,01	<0,01	*
C04AD	Purine derivatives	1,93	1,87	2,14	2,08	2,14
	Pentoxifylline (DDD 1 g/O; 0,3 g/P)	1,91	1,86	2,11	2,07	2,13
C04AX	Other peripheral vasodilators	0,04	0,02	0,01	<0,01	*

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>C05</b>	<b>VASOPROTECTIVES</b>	<b>5,56</b>	<b>5,47</b>	<b>6,17</b>	<b>5,92</b>	<b>3,97</b>
<b>C05A</b>	<b>ANTIHEMORRHOIDS FOR TOPICAL USE</b>	<b>1,33</b>	<b>1,16</b>	<b>1,13</b>	<b>1,02</b>	<b>0,49</b>
C05AA	Products containing corticosteroids	0,35	0,21	0,34	0,51	0,15
C05AX	Other antihemorrhoids for topical use	0,97	0,95	0,79	0,51	0,34
<b>C05B</b>	<b>ANTIVARICOSE THERAPY</b>	<b>2,64</b>	<b>2,50</b>	<b>3,08</b>	<b>3,05</b>	<b>3,03</b>
C05BA	Heparins or heparinoids for topical use	2,64	2,50	3,08	3,05	3,03
<b>C05C</b>	<b>CAPILLARY STABILIZING AGENTS</b>	<b>1,59</b>	<b>1,81</b>	<b>1,95</b>	<b>1,85</b>	<b>0,45</b>
C05CA	Bioflavonoids	1,59	1,81	1,95	1,85	0,45*
<b>C07</b>	<b>BETA BLOCKING AGENTS</b>	<b>15,80</b>	<b>18,33</b>	<b>23,38</b>	<b>23,98</b>	<b>25,88</b>
<b>C07A</b>	<b>BETA BLOCKING AGENTS</b>	<b>15,80</b>	<b>18,33</b>	<b>23,38</b>	<b>23,98</b>	<b>25,88</b>
C07AA	Beta blocking agents, non-selective	1,94	1,95	2,26	2,16	2,17
	Propranolol (DDD 0,16 g)	0,54	0,49	0,50	0,45	0,42
	Sotalol (DDD 0,16 g)	1,40	1,46	1,75	1,71	1,74
C07AB	Beta blocking agents, selective	13,78	16,29	20,98	21,59	23,34
	Metoprolol (DDD 0,15 g)	8,78	11,88	16,16	16,92	18,56
	Atenolol (DDD 0,075 g)	4,57	3,84	3,70	3,18	2,78
<b>C08</b>	<b>CALCIUM CHANNEL BLOCKERS</b>	<b>39,53</b>	<b>43,42</b>	<b>53,91</b>	<b>55,48</b>	<b>56,43</b>
<b>C08C</b>	<b>SELECTIVE CALCIUM CHANNEL BLOKERS WITH MAINLY VASCULAR EFFECTS</b>	<b>37,99</b>	<b>41,93</b>	<b>52,13</b>	<b>53,70</b>	<b>54,52</b>
C08CA	Dihydropyridine derivatives	37,99	41,93	52,13	53,70	54,52
	Amlodipine (DDD 5 mg)	13,77	15,45	23,51	26,87	28,76
	Felodipine (DDD 5 mg)	5,50	8,90	10,13	9,27	8,73
	Nifedipine (DDD 30 mg)	13,12	9,18	8,27	6,79	5,58
	Nitrendipine (DDD 20 mg)	2,14	2,92	3,71	4,44	4,87
	Lacidipine (DDD 4 mg)	3,43	5,43	6,42	6,24	6,48
<b>C08D</b>	<b>SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS</b>	<b>1,53</b>	<b>1,49</b>	<b>1,78</b>	<b>1,78</b>	<b>1,91</b>
C08DA	Phenylalkylamine derivatives	1,42	1,39	1,67	1,67	1,79
	Verapamil (DDD 0,24 g)	1,40	1,37	1,65	1,66	1,76
C08DB	Benzothiazepine derivatives	0,11	0,10	0,11	0,11	0,11
	Diltiazem (DDD 0,24 g)	0,11	0,10	0,11	0,11	0,11


**Kardiovaskulaarravimite kasutamine (C) 2002-2006.**  
**Consumption of cardiovascular drugs (C) 2002-2006.**



DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>C09</b>	<b>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</b>	<b>59,12</b>	<b>71,96</b>	<b>94,87</b>	<b>106,1</b>	<b>120,12</b>
<b>C09A</b>	<b>ACE INHIBITORS, PLAIN</b>	<b>44,27</b>	<b>54,03</b>	<b>68,64</b>	<b>73,58</b>	79,31
C09AA	ACE inhibitors, plain	44,27	54,03	68,64	73,58	79,31
	Captopril (DDD 50 mg)	2,50	1,61	1,26	0,91	0,73
	Enalapril (DDD 10 mg)	19,10	19,15	21,25	21,32	20,92
	Ramipril (DDD 2,5 mg)	16,55	23,92	32,76	36,18	41,82
	Fosinopril (DDD 15 mg)	5,88	8,98	12,72	14,52	15,11
<b>C09B</b>	<b>ACE INHIBITORS, COMBINATIONS</b>	<b>14,55</b>	<b>17,26</b>	<b>24,58</b>	<b>28,38</b>	<b>33,01</b>
C09BA	ACE inhibitors and diuretics	14,55	17,26	24,58	28,38	33,01
<b>C09C</b>	<b>ANGIOTENSIN II ANTAGONISTS, PLAIN</b>	<b>0,26</b>	<b>0,63</b>	<b>1,57</b>	<b>3,28</b>	<b>5,04</b>
C09CA	Angiotensin II antagonists, plain	0,26	0,63	1,57	3,28	5,04
	Losartan (DDD 50 mg)	0,02	0,02	0,02	0,02	0,14
	Valsartan (DDD 80 mg)	0,03	0,03	0,04	0,14	0,16
	Candesartan (DDD 8 mg)	0,12	0,43	1,16	2,24	3,29
	Telmisartan (DDD 40 mg)	0,05	0,11	0,29	0,59	0,77

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>C10</b>	<b>LIPID MODIFYING AGENTS</b>	<b>4,52</b>	<b>6,15</b>	<b>10,20</b>	<b>13,96</b>	<b>14,74</b>
<b>C10A</b>	<b>LIPID MODIFYING AGENTS, PLAIN</b>	<b>4,52</b>	<b>6,15</b>	<b>10,20</b>	<b>13,96</b>	<b>14,74</b>
C10AA	HMG CoA reductase inhibitors	4,40	6,03	10,05	13,70	14,63
	Simvastatin (DDD 15 mg)	2,68	3,40	5,70	7,36	7,19
	Pravastatin (DDD 20 mg)	0,76	1,32	1,62	1,62	1,30
	Fluvastatin (DDD 40 mg)	0,32	0,39	0,33	0,54	0,72
	Atorvastatin (DDD 10 mg)	0,64	0,91	1,43	2,07	2,65
	Rosuvastatin (DDD 10 mg)	<0,01	0,97	2,11	2,77	
C10AB	Fibrates	0,12	0,10	0,13	0,11	0,08

**Statiinide kasutamine (C10AA) 2002-2006.**  
*Consumption of statins (C10AA) 2002-2006.*



DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>D</b>	<b>DERMATOLOGICALS</b>					
<b>D01</b>	<b>ANTIFUNGALS FOR DERMATOLOGICAL USE</b>	<b>0,56</b>	<b>0,72</b>	<b>0,96</b>	<b>1,07</b>	<b>1,15</b>
<b>D01B</b>	<b>ANTIFUNGALS FOR SYSTEMIC USE</b>	<b>0,56</b>	<b>0,72</b>	<b>0,96</b>	<b>1,07</b>	<b>1,15</b>
D01BA	Antifungals for systemic use	0,56	0,72	0,96	1,07	1,15
	Terbinafine (DDD 250 mg)	0,56	0,72	0,96	1,07	1,15



DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>G</b>	<b>GENITO URINARY SYSTEM AND SEX HORMONES</b>					
<b>G01</b>	<b>GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS</b>	<b>1,36</b>	<b>1,28</b>	<b>1,06</b>	<b>1,06</b>	<b>1,03</b>
<b>G01A</b>	<b>ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMB. WITH CORTICOSTEROIDS</b>	<b>1,36</b>	<b>1,28</b>	<b>1,06</b>	<b>1,05</b>	<b>1,03</b>
G01AA	Antibiotics	0,29	0,23	0,16	0,12	0,11
	Clindamycine (DDD 0,1 g)	0,13	0,11	0,12	0,10	0,11
G01AF	Imidazole derivatives	1,07	1,05	0,90	0,94	0,92
	Metronidazole (DDD 0,5 g)	0,36	0,30	0,22	0,22	0,18
	Clotrimazole (DDD 0,1 g)	0,47	0,53	0,56	0,60	0,61
	Econazole (DDD 0,1 g)	0,09	0,08	0,11	0,12	0,13
<b>G02</b>	<b>OTHER GYNECOLOGICALS</b>	<b>2,45</b>	<b>2,48</b>	<b>2,48</b>	<b>2,29</b>	<b>2,81</b>
<b>G02A</b>	<b>OXYTOCICS</b>	<b>0,03</b>	<b>0,04</b>	<b>0,04</b>	<b>0,04</b>	<b>0,03</b>
<b>G02B</b>	<b>CONTRACEPTIVES FOR TOPICAL USE</b>	<b>1,97</b>	<b>1,90</b>	<b>1,74</b>	<b>1,48</b>	<b>1,63</b>
G02BA	Intrauterine contraceptives	0,31	0,29	0,22	0,02	0,02
G02BB	Intravaginal contraceptives	1,66	1,61	1,52	1,46	1,61
<b>G02C</b>	<b>OTHER GYNECOLOGICALS</b>	<b>0,45</b>	<b>0,54</b>	<b>0,70</b>	<b>0,77</b>	<b>1,15</b>
<b>G03</b>	<b>SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</b>	<b>104,06</b>	<b>102,58</b>	<b>111,32</b>	<b>108,43</b>	<b>110,05</b>
<b>G03A</b>	<b>HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE</b>	<b>86,30</b>	<b>86,87</b>	<b>92,52</b>	<b>91,85</b>	<b>95,64</b>
<b>G03B</b>	<b>ANDROGENS</b>	<b>0,06</b>	<b>0,07</b>	<b>1,15</b>	<b>0,24</b>	<b>0,11</b>
<b>G03C</b>	<b>ESTROGENS</b>	<b>8,32</b>	<b>7,24</b>	<b>7,71</b>	<b>6,77</b>	<b>6,43</b>
G03CA	Natural and semisynthetic estrogens, plain	8,32	7,24	7,71	6,77	6,43
	Estradiol (different DDDs)	7,12	6,05	6,47	5,53	5,98
<b>G03D</b>	<b>PROGESTOGENS</b>	<b>3,91</b>	<b>3,06</b>	<b>3,69</b>	<b>3,32</b>	<b>2,00</b>
G03DA	Pregnen (4) derivatives	3,47	2,43	2,80	2,19	0,93
	Medroxyprogesterone (DDD 5 mg/O; 7 mg/P)	3,10	2,12	2,50	1,91	0,57
	Progesterone (DDD 0,3g/O; 5 mg/P; 90 mg/V)	0,37	0,30	0,30	0,27	0,36
G03DB	Pregnadien derivatives	0,21	0,31	0,49	0,59	0,78
G03DC	Estren derivatives	0,24	0,33	0,40	0,54	0,29
	Norethisterone (DDD 5 mg)	0,16	0,17	0,16	0,17	0,18
	Tibolone (DDD 2,5 mg)	0,08	0,16	0,23	0,37	0,11

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>G03F</b>	<b>PROGESTOGENS AND ESTROGENS IN COMBINATION</b>	<b>3,50</b>	<b>3,50</b>	<b>3,50</b>	<b>3,07</b>	<b>2,87</b>
G03FA	Progestogens and estrogens, fixed combinations	2,71	2,74	2,68	2,31	2,21
G03FB	Progestogens and estrogens, sequential preparations	0,79	0,76	0,82	0,76	0,75
<b>G03G</b>	<b>GONADOTROPHINS AND OTHER OVULATION STIMULANTS</b>	<b>0,39</b>	<b>0,32</b>	<b>0,34</b>	<b>0,34</b>	<b>0,45</b>
G03GA	Gonadotrophins	0,22	0,11	0,09	0,11	0,19
G03GB	Ovulation stimulants, synthetic Clomifene (DDD 9 mg)	0,17 0,17	0,21 0,21	0,25 0,25	0,23 0,23	0,25 0,25
G03H	ANTIANDROGENS	1,52	1,48	2,39	2,83	2,55
G03HA	Antiandrogens, plain preparations	0,46	0,59	0,80	0,91	1,03
G03HB	Antiandrogens and estrogens	1,05	0,89	1,59	1,92	1,52
<b>G03X</b>	<b>OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</b>	<b>0,06</b>	<b>0,04</b>	<b>0,02</b>	<b>0,01</b>	<b>&lt;0,01</b>
<b>G04</b>	<b>UROLOGICALS</b>	<b>1,90</b>	<b>2,38</b>	<b>2,79</b>	<b>2,95</b>	<b>3,65</b>
<b>G04B</b>	<b>OTHER UROLOGICAL, INCL. ANTISPASMODICS</b>	<b>1,40</b>	<b>1,39</b>	<b>1,29</b>	<b>1,27</b>	<b>1,12</b>
G04BC	Urinary concrement solvents	0,16	0,13	0,19	0,18	0,21
G04BD	Urinary antispasmodics	0,38	0,38	0,44	0,43	0,52
G04BE	Drugs used in erectile dysfunction	0,18	0,28	0,37	0,41	0,39
G04BX	Other urologicals	0,68	0,60	0,29	0,23	*
<b>G04C</b>	<b>DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY</b>	<b>0,50</b>	<b>0,99</b>	<b>1,49</b>	<b>1,67</b>	<b>2,53</b>
G04CA	Alpha-adrenoreceptor antagonists	0,14	0,21	0,31	0,56	1,28
G04CB	Testosterone-5-alpha reductase inhibitors	0,03	0,05	0,07	0,12	0,22
G04CX	Other drugs used in benign prostatic hypertrophy	0,33	0,73	1,11	0,99	1,02


DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>H</b>	<b>SYSTEMIC HORMONAL PREPARATIONS, EXCL.SEX HORMONES AND INSULINS</b>					
<b>H01</b>	<b>PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</b>	<b>0,27</b>	<b>0,26</b>	<b>0,33</b>	<b>0,34</b>	<b>0,31</b>
<b>H01A</b>	<b>ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</b>	<b>0,05</b>	<b>0,04</b>	<b>0,10</b>	<b>0,08</b>	<b>0,07</b>
<b>H01B</b>	<b>POSTERIOR PITUITARY LOBE HORMONES</b>	<b>0,22</b>	<b>0,22</b>	<b>0,23</b>	<b>0,25</b>	<b>0,23</b>
H01BA	Vasopressin and analogues	0,07	0,08	0,08	0,08	0,06
	Desmopressin (DDD 25 mcg/N ; 0.4 mg/O; 4 mcg/P)	0,07	0,08	0,08	0,08	0,06
H01BB	Oxytocin and derivatives	0,15	0,14	0,15	0,17	0,17
<b>H02</b>	<b>CORTICOSTEROIDS FOR SYSTEMIC USE</b>	<b>5,59</b>	<b>5,35</b>	<b>5,40</b>	<b>5,47</b>	<b>5,53</b>
H02AA	Mineralocorticoids	0,04	0,05	0,05	0,07	0,05
	Fludrocortisone (DDD 0,1 mg)	0,04	0,05	0,05	0,07	0,05
H02AB	Glucocorticoids	5,56	5,30	5,35	5,40	5,48
	Dexamethasone (DDD 1,5 mg)	0,70	0,71	0,77	0,77	0,78
	Methylprednisolone (DDD 7,5 mg/O; 20 mg/P)	1,61	1,61	1,66	1,65	1,61
	Prednisolone (DDD 10 mg)	2,59	2,40	2,31	2,34	2,47
	Triamcinolone (DDD 7,5 mg)	0,47	0,42	0,44	0,47	0,48
<b>H03</b>	<b>THYROID THERAPY</b>	<b>5,25</b>	<b>5,73</b>	<b>6,44</b>	<b>6,96</b>	<b>7,83</b>
<b>H03A</b>	<b>THYROID PREPARATIONS</b>	<b>4,35</b>	<b>5,13</b>	<b>5,76</b>	<b>6,01</b>	<b>6,90</b>
H03AA	Thyroid hormones	4,35	5,13	5,76	6,01	6,90
	Levothyroxine sodium (DDD 0,15 mg)	4,28	5,07	5,73	5,95	6,90
<b>H03B</b>	<b>ANTITHYROID PREPARATIONS</b>	<b>0,61</b>	<b>0,60</b>	<b>0,68</b>	<b>0,94</b>	<b>0,92</b>
H03BA	Thiouracils	0,06	0,10	0,17	0,52	0,59
H03BB	Sulphur-containing imidazole derivatives	0,55	0,50	0,51	0,42	0,33
	Thiamazole (DDD 10 mg)	0,38	0,50	0,51	0,42	0,33

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>J</b>	<b>ANTIINFECTIVES FOR SYSTEMIC USE</b>					
<b>J01</b>	<b>ANTIBACTERIALS FOR SYSTEMIC USE</b>	<b>14,01</b>	<b>13,74</b>	<b>13,47</b>	<b>13,66</b>	<b>13,56</b>
<b>J01A</b>	<b>TETRACYCLINES</b>	<b>2,91</b>	<b>2,99</b>	<b>2,63</b>	<b>2,48</b>	<b>2,41</b>
J01AA	Tetracyclines	2,91	2,99	2,63	2,48	2,41
	Doxycycline (DDD 0,1 g)	2,71	2,78	2,49	2,36	2,29
	Tetracycline (DDD 1 g)	0,19	0,17	0,14	0,12	0,12
<b>J01C</b>	<b>BETA-LACTAM ANTIBACTERIALS, PENICILLINS</b>	<b>5,43</b>	<b>5,24</b>	<b>4,91</b>	<b>5,06</b>	<b>4,91</b>
J01CA	Penicillins with extended spectrum	4,46	4,14	3,57	3,50	3,24
	Ampicillin (DDD 2 g)	0,69	0,56	0,37	0,29	0,22
	Amoxicillin (DDD 1 g)	3,77	3,58	3,20	3,20	3,02
J01CE	Beta-lactamase sensitive penicillins	0,45	0,29	0,35	0,43	0,36
	Benzylopenicillin (DDD 3,6 g)	0,25	0,07	0,05	0,04	0,06
	Phenoxymethylpenicillin (DDD 2 g)	0,17	0,21	0,30	0,39	0,30
J01CF	Beta-lactamase resistant penicillins	0,09	0,12	0,15	0,17	0,18
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors	0,44	0,69	0,83	0,97	1,12
<b>J01D</b>	<b>OTHER BETA-LACTAM ANTIBACTERIALS</b>	<b>0,82</b>	<b>0,85</b>	<b>0,98</b>	<b>1,05</b>	<b>1,16</b>
J01DB	First-generation cephalosporins	0,43	0,44	0,45	0,41	0,40
	Cefalexin (DDD 2 g)	0,06	0,05	0,04	0,03	<0,01
	Cefazolin (DDD 3 g)	0,09	0,08	0,10	0,08	0,07
	Cefadroxil (DDD 2 g)	0,28	0,30	0,31	0,30	0,33
J01DC	Second-generation cephalosporins	0,36	0,38	0,48	0,58	0,70
	Cefuroxim (DDD 0,5 g/O; 3 g/P)	0,24	0,26	0,32	0,42	0,54
	Cefprozil (DDD 1 g)	0,12	0,12	0,16	0,15	0,16
J01DD	Third-generation cephalosporins	0,03	0,03	0,03	0,04	0,04
J01DH	Carbapenems	0,01	0,01	0,01	0,01	0,02
<b>J01E</b>	<b>SULFONAMIDES AND TRIMETHOPRIM</b>	<b>1,07</b>	<b>0,96</b>	<b>0,76</b>	<b>0,64</b>	<b>0,65</b>
J01EA	Trimethoprim and derivatives	0,02	0,04	0,02	0,02	0,02
J01ED	Long-acting sulfonamides	0,11	0,08	0,05	0,02	0,02
	Sulfadimethoxine (DDD 0,5 g)	0,11	0,08	0,05	0,02	0,02
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives	0,94	0,85	0,69	0,60	0,63
	Sulfamethoxazole + trimethoprim (different DDDs)	0,69	0,58	0,45	0,37	0,37
	Sulfametrole + trimethoprim (different DDDs)	0,24	0,27	0,24	0,23	0,26

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>J01F</b>	<b>MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS</b>	<b>1,31</b>	<b>1,28</b>	<b>1,60</b>	<b>1,85</b>	<b>2,00</b>
J01FA	Macrolides	1,23	1,20	1,50	1,75	1,88
	Erythromycin (DDD 1 g)	0,69	0,49	0,34	0,21	0,17
	Clarithromycin (DDD 0,5 g/O; 1 g/P)	0,28	0,36	0,76	1,20	1,38
	Azithromycin (DDD 0,3 g/O; 0,5 g/P)	0,20	0,28	0,34	0,30	0,28
J01FF	Lincosamides	0,08	0,08	0,10	0,10	0,12
<b>J01G</b>	<b>AMINOGLYCOSIDE ANTIBACTERIALS</b>	<b>0,28</b>	<b>0,26</b>	<b>0,25</b>	<b>0,20</b>	<b>0,13</b>
J01GB	Other aminoglycosides	0,28	0,26	0,23	0,20	0,13
	Gentamicin (DDD 0,24 g)	0,26	0,22	0,20	0,18	0,11
<b>J01M</b>	<b>QUINOLONE ANTIBACTERIALS</b>	<b>0,74</b>	<b>0,82</b>	<b>0,96</b>	<b>1,02</b>	<b>1,09</b>
J01MA	Fluoroquinolones	0,74	0,82	0,96	1,02	1,09
	Ofloxacin (DDD 0,4 g)	0,10	0,08	0,14	0,19	0,19
	Ciprofloxacin (DDD 1 g/O; 0,5 g/P)	0,46	0,55	0,60	0,58	0,61
	Norfloxacin (DDD 0,8 g)	0,18	0,18	0,22	0,24	0,28
<b>J01X</b>	<b>OTHER ANTIBACTERIALS</b>	<b>1,45</b>	<b>1,38</b>	<b>1,39</b>	<b>1,36</b>	<b>1,21</b>
J01XD	Imidazole derivatives	0,88	0,88	0,88	0,83	0,64
	Metronidazole (DDD 1,5 g)	0,88	0,88	0,88	0,83	0,64
J01XE	Nitrofurans derivatives	0,54	0,47	0,49	0,52	0,54
	Nitrofurantoin (DDD 0,2 g)	0,54	0,47	0,49	0,52	0,54

#### Antibakteriaalsete ainete kasutamine (J01) 2002-2006.

Consumption of antibacterials for systemic use (J01) 2002-2006.




DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>J02</b>	<b>ANTIMYCOTICS FOR SYSTEMIC USE</b>	<b>1,16</b>	<b>0,75</b>	<b>0,60</b>	<b>0,54</b>	<b>0,55</b>
<b>J02A</b>	<b>ANTIMYCOTICS FOR SYSTEMIC USE</b>	<b>1,16</b>	<b>0,75</b>	<b>0,60</b>	<b>0,54</b>	<b>0,55</b>
J02AA	Antibiotics	0,03	0,01	0,02	0,01	0,02
J02AB	Imidazole derivatives Ketoconazole (DDD 0,2 g)	0,88 0,88	0,52 0,52	0,38 0,38	0,31 0,31	0,30 0,30
J02AC	Triazole derivatives	0,24	0,22	0,20	0,21	0,24
<b>J04</b>	<b>ANTIMYCOBACTERIALS</b>	<b>0,33</b>	<b>0,93</b>	<b>0,32</b>	<b>0,31</b>	<b>0,47</b>
<b>J04A</b>	<b>DRUGS FOR TREATMENT OF TUBERCULOSIS</b>	<b>0,32</b>	<b>0,92</b>	<b>0,31</b>	<b>0,29</b>	<b>0,46</b>
J04AB	Antibiotics Rifampicin (DDD 0,6 g)	0,01 0,01	0,11 0,07	0,02 0,02	0,02 0,02	0,06 0,05
J04AC	Hydrazides Isoniazid (DDD 0,3 g)	0,08 0,08	0,14 0,14	0,02 0,02	0,11 0,11	<0,01 <0,01
J04AK	Other drugs for treatment of tuberculosis Pyrazinamide (DDD 1,5 g) Ethambutol (DDD 1,2 g)	0,12 0,11 <0,01	0,47 0,34 <0,01	0,07 0,07 0,07	0,04 0,02 0,01	0,37 0,25 0,12
J04AM	Combinations of drugs for treatment of tuberculosis	0,10	0,17	0,15	0,12	*
<b>J05</b>	<b>ANTIVIRALS FOR SYSTEMIC USE</b>	<b>0,11</b>	<b>0,11</b>	<b>0,14</b>	<b>0,37</b>	<b>0,79</b>
<b>J05A</b>	<b>DIRECT ACTING ANTIVIRALS</b>	<b>0,11</b>	<b>0,11</b>	<b>0,14</b>	<b>0,37</b>	<b>0,79</b>
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	0,03	0,04	0,05	0,10	0,10
J05AE	Protease inhibitors	0,03	0,02	0,02	0,04	0,05
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors	0,04	0,04	0,05	0,16	0,34
J05AG	Non-nucleoside reverse transcriptase inhibitors	0,01	0,01	0,02	0,06	0,20
J05AH	Neuraminidase inhibitors	<0,01	<0,01	<0,01	0,01	0,08

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>L</b>	<b>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>					
<i>L02</i>	<i>ENDOCRINE THERAPY</i>	<i>1,16</i>	<i>1,30</i>	<i>1,29</i>	<i>1,38</i>	<i>1,50</i>
<b>L02A</b>	<b>HORMONES AND RELATED AGENTS</b>	<b>0,15</b>	<b>0,11</b>	<b>0,11</b>	<b>0,15</b>	<b>0,18</b>
<b>L02B</b>	<b>HORMONE ANTAGONISTS AND RELATED AGENTS</b>	<b>1,01</b>	<b>1,19</b>	<b>1,18</b>	<b>1,23</b>	<b>1,32</b>
L02BA	Anti-estrogens	0,99	1,10	0,98	0,91	0,72
L02BG	Enzyme inhibitors	0,02	0,09	0,20	0,32	0,60

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>M</b>	<b>MUSCULO-SKELETAL SYSTEM</b>					
<i>M01</i>	<i>ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS</i>	<i>40,13</i>	<i>39,16</i>	<i>42,54</i>	<i>43,54</i>	<i>49,83</i>
<b>M01A</b>	<b>ANTIINFLAMMATORY / ANTIRHEUMATIC PRODUCTS, NON-STERIODS</b>	<b>40,11</b>	<b>39,14</b>	<b>42,52</b>	<b>43,51</b>	<b>49,83</b>
M01AB	Acetic acid derivatives and related substances	18,93	16,58	16,71	15,90	15,86
	Indometacin (DDD 0,1 g)	0,81	0,56	0,52	0,48	0,40
	Diclofenac (DDD 0,1 g)	17,94	15,92	16,12	15,35	15,39
M01AC	Oxicams	0,88	0,88	1,55	2,07	3,13
	Piroxicam (DDD 20 mg)	0,34	0,23	0,22	0,16	<0,01
	Lornoxicam (DDD 12 mg)	0,15	0,16	0,41	0,66	0,78
	Meloxicam (DDD 15 mg)	0,38	0,49	0,92	1,25	2,35
M01AE	Propionic acid derivatives	17,43	18,18	20,04	21,37	22,42
	Ibuprofen (DDD 1,2 g)	16,54	17,44	19,10	20,49	21,58
M01AG	Fenamates	1,14	0,64	0,08	0,05	0,04
M01AH	Coxibs	0,71	1,11	1,40	0,25	1,92
M01AX	Other antiinflammatory/antirheumatic agents, non-steroids	1,03	1,75	2,74	3,89	6,43
	Glucosamine (DDD 1,5 g)	1,03	1,72	2,59	3,58	5,93
<b>M01C</b>	<b>SPECIFIC ANTIRHEUMATIC AGENTS</b>	<b>0,02</b>	<b>0,02</b>	<b>0,02</b>	<b>0,02</b>	<b>0,01</b>

**Mittesteroidsete põletiku ja reumavastaste ainete kasutamine (M01A) 2002-2006.**  
**Consumption of antiinflammatory and antirheumatic products, non-steroids (M01A) 2002-2006.**




DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>M03</b>	<b>MUSCLE RELAXANTS</b>	<b>0,45</b>	<b>0,40</b>	<b>0,40</b>	<b>0,46</b>	<b>0,52</b>
<b>M03B</b>	<b>MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS</b>	<b>0,45</b>	<b>0,40</b>	<b>0,40</b>	<b>0,46</b>	<b>0,52</b>
M03BX	Other centrally acting agents	0,45	0,40	0,40	0,46	0,52
	Baclofen (DDD 50 mg)	0,10	0,09	0,08	0,12	0,12
	Tizanidine (DDD 12 mg)	0,26	0,26	0,29	0,32	0,39
	Tolperisone (DDD 0,2 g)	0,09	0,05	0,03	0,02	0,01
<b>M04</b>	<b>ANTIGOUT PREPARATIONS</b>	<b>0,68</b>	<b>0,74</b>	<b>0,95</b>	<b>1,13</b>	<b>1,39</b>
<b>M04A</b>	<b>ANTIGOUT PREPARATIONS</b>	<b>0,68</b>	<b>0,74</b>	<b>0,95</b>	<b>1,13</b>	<b>1,39</b>
M04AA	Preparations inhibiting uric acid production	0,68	0,73	0,95	1,12	1,37
	Allopurinol (DDD 0,4 g)	0,68	0,73	0,95	1,12	1,37
<b>M05</b>	<b>DRUGS FOR TREATMENT OF BONE DISEASES</b>	<b>0,45</b>	<b>0,52</b>	<b>0,81</b>	<b>0,99</b>	<b>1,35</b>
<b>M05B</b>	<b>DRUGS AFFECTING MINERALIZATION</b>	<b>0,45</b>	<b>0,52</b>	<b>0,81</b>	<b>0,99</b>	<b>1,35</b>
M05BA	Bisphosphonates	0,45	0,52	0,81	0,99	0,79
M05BB	Bisphosphonates, combinations					0,52



DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>N</b>	<b>NERVOUS SYSTEM</b>					
<b>N02</b>	<b>ANALGESICS</b>	<b>10,74</b>	<b>10,79</b>	<b>11,29</b>	<b>11,89</b>	<b>13,53</b>
<b>N02A</b>	<b>OPIOIDS</b>	<b>1,73</b>	<b>1,87</b>	<b>2,38</b>	<b>2,69</b>	<b>2,78</b>
N02AA	Natural opium alkaloids Morphine (DDD 0,1 g/O; 30 mg/R, P)	0,24 0,24	0,24 0,20	0,31 0,22	0,25 0,19	0,28 0,20
N02AB	Phenylpiperidine derivatives Fentanyl (DDD 1,2 mg/TD; 0,6 mg/SL)	0,08 0,04	0,14 0,11	0,19 0,16	0,27 0,24	0,28 0,25
N02AC	Diphenylpropylamine derivatives Methadone (DDD 0,025 g)	0,10 0,10	0,25 0,25	0,47 0,47	0,63 0,63	0,83 0,83
N02AX	Other opioids Tramadol (DDD 0,3 g)	1,31 0,72	1,23 0,85	1,41 0,99	1,55 1,10	1,39 1,39

**Opioidide kasutamine (N02A) 2002-2006.**  
*Consumption of opioids (N02A) 2002-2006.*




<b>N02B</b>	<b>OTHER ANALGESICS AND ANTIPYRETICS</b>	<b>8,96</b>	<b>8,86</b>	<b>8,84</b>	<b>9,12</b>	<b>10,66</b>
N02BA	Salicylic acid and derivatives Acetylsalicylic acid (DDD 3 g)	3,70 3,36	2,99 2,69	2,92 2,65	2,61 2,38	2,42 2,16
N02BB	Pyrazolones Metamizole sodium (DDD 3 g)	0,76 0,76	0,58 0,58	0,44 0,44	0,36 0,36	0,31 0,31
N02BE	Anilides Paracetamol (DDD 3 g)	4,50 2,95	5,29 3,50	5,47 3,41	6,16 3,85	7,92 4,31
<b>N02C</b>	<b>ANTIMIGRAINE PREPARATIONS</b>	<b>0,05</b>	<b>0,06</b>	<b>0,07</b>	<b>0,08</b>	<b>0,09</b>
N02CC	Selective 5HT1-receptor agonists	0,05	0,06	0,07	0,08	0,09

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>N03</b>	<b>ANTIEPILEPTICS</b>	<b>3,78</b>	<b>4,09</b>	<b>4,61</b>	<b>4,78</b>	<b>5,11</b>
<b>N03A</b>	<b>ANTIEPILEPTICS</b>	<b>3,78</b>	<b>4,09</b>	<b>4,61</b>	<b>4,78</b>	<b>5,11</b>
N03AA	Barbiturates and derivatives	0,52	0,51	0,51	0,46	0,44
	Phenobarbital (DDD 0,1 g)	0,41	0,40	0,41	0,37	0,36
N03AB	Hydantoin derivatives	0,09	0,09	0,09	0,08	0,07
N03AE	Benzodiazepine derivatives	0,28	0,33	0,43	0,53	0,68
N03AF	Carboxamide derivatives	2,16	2,22	2,44	2,50	2,53
	Carbamazepine (DDD 1 g)	2,16	2,21	2,34	2,22	2,18
N03AG	Fatty acid derivatives	0,58	0,70	0,86	0,88	0,94
N03AX	Other antiepileptics	0,14	0,24	0,28	0,34	0,42
<b>N04</b>	<b>ANTI-PARKINSON DRUGS</b>	<b>2,60</b>	<b>2,81</b>	<b>2,96</b>	<b>2,80</b>	<b>2,73</b>
<b>N04A</b>	<b>ANTICHOLINERGIC AGENTS</b>	<b>0,86</b>	<b>0,88</b>	<b>0,80</b>	<b>0,76</b>	<b>0,74</b>
N04AA	Tertiary amines	0,86	0,88	0,80	0,76	0,74
	Trihexyphenidyl (DDD 10 mg)	0,85	0,88	0,79	0,74	0,73
<b>N04B</b>	<b>DOPAMINERGIC AGENTS</b>	<b>1,74</b>	<b>1,92</b>	<b>2,16</b>	<b>2,04</b>	<b>1,99</b>
N04BA	Dopa and dopa derivatives	1,17	1,29	1,42	1,28	1,22
N04BB	Adamantane derivatives	0,47	0,48	0,52	0,45	0,42
N04BC	Dopamine agonists	0,09	0,13	0,22	0,30	0,33
N04BD	Monoamine oxidase type B inhibitors	0,01	0,02	0,01	0,01	0,01
<b>N05</b>	<b>PSYCHOLEPTICS</b>	<b>26,74</b>	<b>26,24</b>	<b>29,12</b>	<b>29,62</b>	<b>31,99</b>
<b>N05A</b>	<b>ANTIPSYCHOTICS</b>	<b>4,29</b>	<b>4,51</b>	<b>4,47</b>	<b>4,62</b>	<b>4,48</b>
N05AA	Phenothiazines with aliphatic side-chain	0,35	0,34	0,32	0,27	0,27
	Chlorpromazine (DDD 0,1 g/P; 0,3 g/O,R)	0,25	0,24	0,21	0,18	0,18
N05AB	Phenothiazine with piperazine structure	0,14	0,10	0,08	0,09	0,09
N05AC	Phenothiazine with piperidine structure	0,15	0,16	0,16	0,06	<0,01
N05AD	Butyrophenone derivatives	1,75	1,88	1,83	1,74	1,39
	Haloperidol (DDD 8 mg/O,P; 3,3 mg/P depot)	1,41	1,51	1,46	1,32	1,01
N05AF	Thioxanthene derivatives	1,24	1,30	1,09	1,13	0,95
	Chlorprothixene (DDD 0,3 g/O; 50 mg/P)	0,29	0,33	0,31	0,36	0,39

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
N05AH	Dibenzodiazepine and dibenzoxazepine derivatives	0,27	0,34	0,52	0,76	1,04
	Olanzapine (DDD 10 mg)	0,02	0,01	0,08	0,26	0,41
	Quetiapine (DDD 0,4 g)	0,03	0,03	0,13	0,20	0,31
N05AL	Benzamides	0,06	0,09	0,11	0,11	0,12
N05AN	Lithium	0,15	0,14	0,14	0,14	0,14
N05AX	Other antipsychotics	0,18	0,17	0,21	0,32	0,41
	Risperidone (DDD 5 mg/O; 1,8 mg/P depot)	0,18	0,17	0,21	0,32	0,41
<b>N05B</b>	<b>ANXIOLYTICS</b>	<b>9,38</b>	<b>10,35</b>	<b>12,22</b>	<b>12,87</b>	<b>14,53</b>
N05BA	Benzodiazepine derivatives	9,38	10,35	12,22	12,87	14,53
	Diazepam (DDD 10 mg)	4,96	5,44	6,13	6,01	6,90
	Oxazepam (DDD 50 mg)	0,73	0,49	0,52	0,25	0,03
	Bromazepam (DDD 10 mg)	0,83	0,88	1,01	1,08	1,22
	Alprazolam (DDD 1 mg)	2,80	3,49	4,48	5,48	6,31
<b>N05C</b>	<b>HYPNOTICS AND SEDATIVES</b>	<b>13,07</b>	<b>11,38</b>	<b>12,42</b>	<b>12,13</b>	<b>12,98</b>
N05CD	Benzodiazepine derivatives	4,33	3,81	3,52	3,53	3,74
	Nitrazepam (DDD 5 mg)	2,69	2,80	2,92	2,86	2,96
	Flunitrazepam (DDD 1 mg)	1,42	0,78	0,23	0,14	*
	Midazolam (DDD 15 mg)	0,16	0,18	0,33	0,47	0,71
N05CF	Benzodiazepine related drugs	5,06	5,43	6,82	7,85	9,20
	Zopiclone (DDD 7,5 mg)	4,50	4,90	6,08	6,96	8,12
	Zolpidem (DDD 10 mg)	0,56	0,53	0,74	0,89	1,08
N05CM	Other hypnotics and sedatives	3,67	2,14	2,08	0,75	0,02*
	Valeriana	<0,01	0,12	0,34	<0,01	0,02
<b>N06</b>	<b>PSYCHOANALEPTICS</b>	<b>12,60</b>	<b>13,76</b>	<b>15,65</b>	<b>17,37</b>	<b>18,20</b>
<b>N06A</b>	<b>ANTIDEPRESSANTS</b>	<b>8,96</b>	<b>10,28</b>	<b>11,89</b>	<b>12,36</b>	<b>13,17</b>
N06AA	Non-selective monoamine reuptake inhibitors	3,27	3,13	3,16	2,90	2,69
	Amitriptyline (DDD 75 mg)	1,67	1,87	1,92	1,83	1,81
	Nortriptyline (DDD 75 mg/O; 30 mg/P)	1,45	1,11	1,06	0,94	0,78
N06AB	Selective serotonin reuptake inhibitors	5,40	6,79	8,30	8,79	9,16
	Fluoxetine (DDD 20 mg)	2,20	2,59	2,76	2,62	2,52
	Citalopram (DDD 20 mg)	1,95	1,01	1,63	1,91	2,05
	Paroxetine (DDD 20 mg)	0,69	0,88	1,29	1,53	1,65
	Sertraline (DDD 50 mg)	0,14	0,25	0,80	1,04	1,22
	Escitalopram (DDD 10 mg)	0,38	2,00	1,78	1,66	1,70
N06AG	Monoamine oxidase type A inhibitors	0,02	0,02	0,02	0,01	<0,01
N06AX	Other antidepressants	0,27	0,35	0,41	0,66	1,31

**Antidepressantide kasutamine (N06A) 2002-2006.**  
**Consumption of antidepressants (N06A) 2002-2006.**



DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>N06B</b>	<b>PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS</b>	<b>3,63</b>	<b>3,46</b>	<b>3,73</b>	<b>4,96</b>	<b>4,97</b>
N06BC	Xanthine derivatives	0,40	0,42	0,05	0,05	<0,01
N06BX	Other psychostimulants and nootropics	3,22	3,03	3,66	4,90	4,94
<b>N07</b>	<b>OTHER NERVOUS SYSTEM DRUGS</b>	<b>4,24</b>	<b>4,17</b>	<b>4,67</b>	<b>4,75</b>	<b>5,19</b>
<b>N07A</b>	<b>PARASYMPATHOMIMETICS</b>	<b>0,18</b>	<b>0,20</b>	<b>0,23</b>	<b>0,24</b>	<b>0,26</b>
N07AA	Anticholinesterases	0,18	0,20	0,23	0,24	0,26
<b>N07B</b>	<b>DRUGS USED IN ADDICTIVE DISORDERS</b>	<b>0,23</b>	<b>0,31</b>	<b>0,54</b>	<b>0,83</b>	<b>1,16</b>
N07BA	Drugs used in nicotine dependence	0,21	0,24	0,33	0,66	0,96
	Nicotine (DDD 30 mg/O; 14 mg/TD; 60 mg/Inhal)	0,21	0,24	0,33	0,66	0,95
<b>N07C</b>	<b>ANTIVERTIGO PREPARATIONS</b>	<b>3,83</b>	<b>3,66</b>	<b>3,90</b>	<b>3,68</b>	<b>3,76</b>
N07CA	Antivertigo preparations	3,83	3,66	3,90	3,68	3,76
	Betahistine (DDD 24 mg)	0,26	0,36	0,60	0,80	1,39
	Cinnarizine (DDD 90 mg)	3,57	3,30	3,30	2,88	2,37


DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>P</b>	<b>ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</b>					
<b>P01</b>	<b>ANTIPROTOZOALS</b>	<b>0,27</b>	<b>0,34</b>	<b>0,43</b>	<b>0,44</b>	<b>0,47</b>
<b>P01A</b>	<b>AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES</b>	<b>0,02</b>	<b>0,02</b>	<b>0,02</b>	<b>0,02</b>	<b>0,01</b>
P01AB	Nitroimidazole derivatives	0,02	0,02	0,02	0,02	0,01
<b>P01B</b>	<b>ANTIMALARIALS</b>	<b>0,24</b>	<b>0,32</b>	<b>0,41</b>	<b>0,42</b>	<b>0,46</b>
<b>P02</b>	<b>ANTIHELMINTICS</b>	<b>0,18</b>	<b>0,16</b>	<b>0,15</b>	<b>0,15</b>	<b>0,14</b>
<b>P02C</b>	<b>ANTINEMATODAL AGENTS</b>	<b>0,18</b>	<b>0,16</b>	<b>0,15</b>	<b>0,15</b>	<b>0,14</b>
P02CA	Benzimidazole derivatives Mebendazole (DDD 0,2 g)	0,17 0,17	0,15 0,15	0,14 0,14	0,15 0,15	0,13 0,13
P02CE	Imidazothiazole derivatives Levamisole (DDD 0,15 g)	0,01 0,01	0,01 0,01	0,01 0,01	<0,01 <0,01	<0,01 <0,01
<b>P03</b>	<b>ECTOPARASITICIDES, INCL. SCABICIDES INSECTICIDES AND REPELLENTS</b>	<b>0,12</b>	<b>0,09</b>	<b>0,08</b>	<b>0,08</b>	<b>0,06</b>
<b>P03A</b>	<b>ECTOPARASITICIDES, INCL. SCABICIDES</b>	<b>0,12</b>	<b>0,09</b>	<b>0,08</b>	<b>0,08</b>	<b>0,06</b>
P03AX	Other ectoparasiticides, incl. scabicides Benzyl benzoate	0,03 0,03	0,04 0,04	0,03 0,03	0,03 0,03	0,02 0,02

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>R</b>	<b>RESPIRATORY SYSTEM</b>					
<b>R01</b>	<b>NASAL PREPARATIONS</b>	<b>17,54</b>	<b>17,95</b>	<b>19,23</b>	<b>20,45</b>	<b>24,09</b>
<b>R01A</b>	<b>DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE</b>	<b>16,23</b>	<b>16,36</b>	<b>17,75</b>	<b>18,89</b>	<b>22,30</b>
R01AA	Sympathomimetics, plain	12,99	13,19	14,55	15,47	18,26
	Xylomethazoline (DDD 0,8 mg)	11,29	11,53	13,17	14,77	17,76
	Naphazoline (DDD 0,4 mg)	0,71	0,67	0,46	0,35	0,50
R01AC	Antiallergic agents, excl, corticosteroids	0,20	0,17	0,21	0,20	0,20
R01AD	Corticosteroids	2,79	2,73	2,72	2,91	3,46
	Beclometasone (DDD 0,4 mg)	0,87	0,62	0,61	0,54	0,51
	Budesonide (DDD 0,2 mg)	1,32	1,41	1,23	1,24	1,40
	Fluticasone (DDD 0,2 mg)	0,12	0,10	0,12	0,25	0,53
	Mometasone (DDD 0,2 mg)	0,48	0,60	0,76	0,87	1,01
<b>R01B</b>	<b>NASAL DECONGESTANTS FOR SYSTEMIC USE</b>	<b>1,31</b>	<b>1,59</b>	<b>1,48</b>	<b>1,56</b>	<b>1,79</b>
R01BA	Sympathomimetics	1,31	1,59	1,48	1,56	1,79
<b>R02</b>	<b>THROAT PREPARATIONS</b>	<b>4,76</b>	<b>6,55</b>	<b>8,24</b>	<b>7,85</b>	<b>2,02</b>
<b>R02A</b>	<b>THROAT PREPARATIONS</b>	<b>4,76</b>	<b>6,55</b>	<b>8,24</b>	<b>7,85</b>	<b>2,02</b>
R02AA	Antiseptics	4,46	6,20	7,95	7,54	2,02*
<b>R03</b>	<b>DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</b>	<b>16,18</b>	<b>16,02</b>	<b>17,35</b>	<b>16,11</b>	<b>16,49</b>
<b>R03A</b>	<b>ADRENERGICS, INHALANTS</b>	<b>8,63</b>	<b>8,66</b>	<b>9,29</b>	<b>9,14</b>	<b>9,93</b>
R03AC	Selective beta-2-adrenoreceptor agonists	8,03	7,89	7,88	6,72	6,48
	Salbutamol (different DDDs)	3,74	3,93	4,19	3,45	3,33
	Fenoterol (different DDDs)	2,67	1,85	0,98	0,81	0,73
	Salmeterol (DDD 0,1 mg)	1,10	1,04	1,23	0,98	0,85
	Formoterol (DDD 24 mcg)	0,26	0,88	1,39	1,45	1,57
R03AK	Adrenergics and other drugs for obstructive airway diseases	0,60	0,77	1,41	2,42	3,44
<b>R03B</b>	<b>OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS</b>	<b>4,81</b>	<b>4,86</b>	<b>5,55</b>	<b>4,43</b>	<b>4,04</b>
R03BA	Glucocorticosteroids	4,11	4,05	4,57	3,56	3,18
	Beclometasone (different DDDs)	3,55	3,48	3,96	2,96	2,43
	Budesonide (different DDDs)	0,49	0,42	0,45	0,46	0,61

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
R03BB	Anticholinergics Ipratropium bromide (different DDDs)	0,70	0,81	0,98	0,87	0,85
<b>R03C</b>	<b>ADRENERGICS FOR SYSTEMIC USE</b>	<b>0,20</b>	<b>0,23</b>	<b>0,24</b>	<b>0,27</b>	<b>0,32</b>
R03CA	Alpha- and beta-adrenoreceptor agonists	0,02	0,03	0,02	0,02	0,02
R03CC	Selective beta-2-adrenoreceptor agonists Salbutamol (DDD 12 mg)	0,18	0,20	0,22	0,25	0,29
<b>R03D</b>	<b>OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</b>	<b>2,53</b>	<b>2,27</b>	<b>2,27</b>	<b>2,27</b>	<b>2,19</b>
R03DA	Xanthines Theophylline (DDD 0,4 g) Aminophylline (DDD 0,6 g)	2,48	2,21	2,15	1,97	1,82
R03DC	Leukotriene receptor antagonists	0,06	0,05	0,12	0,29	0,36

#### Astmaravimite kasutamine (R03) 2002-2006.

*Consumption of drugs for obstructive airway diseases (R03) 2002-2006.*



DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>R05</b>	<b>COUGH AND COLD PREPARATIONS</b>	<b>10,87</b>	<b>12,96</b>	<b>12,60</b>	<b>12,53</b>	<b>6,38</b>
<b>R05C</b>	<b>EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS</b>	<b>7,11</b>	<b>8,52</b>	<b>8,45</b>	<b>8,69</b>	<b>6,17</b>
R05CA	Expectorants	1,22	1,20	1,21	1,29	0,30*
R05CB	Mucolytics	5,89	7,31	7,24	7,41	5,86
	Acetylcysteine (DDD 0,5 g)	1,78	2,86	2,88	3,00	2,93
	Bromhexine (DDD 24 mg)	1,48	1,35	1,29	1,26	1,22
	Ambroxol (DDD 0,12 g)	2,49	2,95	2,94	3,07	1,61
<b>R05D</b>	<b>COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS</b>	<b>0,34</b>	<b>0,27</b>	<b>0,21</b>	<b>0,18</b>	<b>0,20</b>
R05DA	Opium alkaloids and derivatives	0,25	0,15	0,07	0,05	0,05
	Codeine (DDD 0,1 g)	0,09	0,11	0,02	< 0,01	< 0,01
R05DB	Other cough suppressants	0,09	0,13	0,14	0,13	0,15
<b>R05F</b>	<b>COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS</b>	<b>3,42</b>	<b>4,17</b>	<b>3,94</b>	<b>3,66</b>	<b>&lt; 0,01</b>
<b>R06</b>	<b>ANTI-HISTAMINES FOR SYSTEMIC USE</b>	<b>6,17</b>	<b>6,15</b>	<b>7,30</b>	<b>8,11</b>	<b>8,42</b>
R06AA	Aminoalkyl ethers	0,93	0,77	0,71	0,60	0,50
	Clemastine (DDD 2 mg)	0,64	0,56	0,51	0,50	0,49
R06AE	Piperazine derivatives	2,27	2,16	2,90	3,28	3,70
R06AX	Other antihistamines for systemic use	2,96	3,21	3,68	4,22	4,20
	Loratadine (DDD 10 mg)	1,77	1,80	2,11	2,38	2,65
	Ebastine (DDD 10 mg)	0,39	0,43	0,46	0,61	0,78
	Desloratadine (DDD 5 mg)	0,53	0,77	0,94	1,06	0,63

DDD/1000 inhabitants/day		2002	2003	2004	2005	2006
<b>S</b>	<b>SENSORY ORGANS</b>					
<b>S01</b>	<b>OPHTHALMOLOGICALS</b>	<b>7,13</b>	<b>7,97</b>	<b>9,33</b>	<b>9,92</b>	<b>12,06</b>
<b>S01E</b>	<b>ANTIGLAUCOMA PREPARATIONS AND MIOTICS</b>	<b>7,13</b>	<b>7,97</b>	<b>9,33</b>	<b>9,92</b>	<b>12,06</b>
S01EB	Parasympathomimetics	0,43	0,26	0,22	0,16	0,13
	Pilocarpine (DDD 0,4 ml)	0,29	0,16	0,13	0,10	0,08
S01EC	Carbonic anhydrase inhibitors	0,24	0,26	0,34	0,38	1,15
S01ED	Beta blocking agents	6,04	6,25	6,91	6,97	7,59
	Timolol (DDD 0,2 ml)	3,49	3,48	3,72	3,28	3,17
	Betaxolol (DDD 0,2 ml)	1,34	1,38	1,36	1,36	1,45
S01EX	Other antiglaucoma preparations	0,42	1,19	1,63	2,41	3,17





**Ravimiamet**  
**State Agency of Medicines**